New England Independent Review Board Joins the WIRB-Copernicus Group
New addition expands WCG's New England presence and increases its expertise in all phases of clinical research
WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that New England Independent Review Board (IRB) has joined the group of companies. Based near Boston, MA, New England IRB expands WCG’s presence in the important New England clinical research hub and further increases its expertise in all phases of drug, medical device and behavioral research.
WCG Chairman and CEO Donald A. Deieso, Ph.D., commented, “We are delighted to welcome New England IRB to the WCG family. New England IRB is recognized for its focus on quality – it has an exceptional regulatory and compliance record – and for providing extraordinary, personalized servicetoits customers.” He added, “The level of innovation and clinical research leadership in the New England region has grown substantially in the pharmaceutical and biotech industry. It is important that we provide a strong regional presence for our clients.”
Founded in 1988, New England IRB was one of the first national, central IRBs dedicated to ensuring the rights and welfare of research study participants.
“We are excited to begin this new phase in New England IRB’s growth,” said New England IRB President James Saunders. “We can now offer our clients access to technologies and processes that will make the clinical trial process more efficient.”
New England IRB will continue to operate independently and will retain its leadership, personnel, and brand. WCG will provide New England IRB with access to technologies, capital and corporate support.
New England IRB joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, and IRBNet as a member of the WCG family of companies. With the addition of New England IRB, WCG has 14 individual IRB panels, all accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), reviewing clinical research.
“Having maintained its AAHRPP accreditation since 2004, New England IRB has demonstrated itself as a very high quality review board,”said AAHRPP President and CEO Elyse Summers, J.D. “WCG’s commitment to human subjects’ protection and AAHRPP accreditation across its wide spectrum of clients redounds ultimately to the benefit of the volunteers who make the entire human research enterprise possible,” she added.
Financial details about the transaction were not disclosed.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
